See more : CSSC (Hong Kong) Shipping Company Limited (3877.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Imagin Medical Inc. (IMEXF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Imagin Medical Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Verb Technology Company, Inc. (VERB) Income Statement Analysis – Financial Results
- Ju-Kao Engineering Co., Ltd. (1594.TWO) Income Statement Analysis – Financial Results
- Tinexta S.p.A. (0RIW.L) Income Statement Analysis – Financial Results
- Canadian Utilities Limited (CUTLF) Income Statement Analysis – Financial Results
- Trident Brands Incorporated (TDNT) Income Statement Analysis – Financial Results
Imagin Medical Inc. (IMEXF)
About Imagin Medical Inc.
Imagin Medical Inc. operates as a surgical imaging company focusing on bladder cancer. The company is developing the i/Blue Imaging System to meet the BLC needs of urologists. Imagin Medical Inc. was founded in 1986 and is headquartered in Vancouver, Canada.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 646.00 | 1.88K | 2.06K | 0.00 |
| Cost of Revenue | 47.13K | 29.39K | 32.18K | 24.50K | 13.98K | 14.24K | 14.55K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -47.13K | -29.39K | -32.18K | -24.50K | -13.98K | -14.24K | -14.55K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 646.00 | 1.88K | 2.06K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 2.05M | 1.73M | 2.13M | 2.20M | 806.85K | 327.36K | 238.72K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.22M | 2.11M | 2.22M | 2.32M | 7.13M | 1.19M | 1.62M | 390.48K | 549.65K | 554.30K | 632.71K | 981.43K | 593.39K | 700.07K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 136.77K | 0.00 | 17.70K | 83.67K | 35.01K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.35M | 2.11M | 2.22M | 2.32M | 7.13M | 1.19M | 1.62M | 390.48K | 549.65K | 554.30K | 632.71K | 981.43K | 593.39K | 700.07K | 1.06M | 2.20M | 1.39M | 1.07M | 133.52K | 148.40K | 168.22K | 156.41K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -52.26K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3.42M | 0.00 | 42.26K | -584.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 3.40M | 3.87M | 4.38M | 4.55M | 7.95M | 1.53M | 1.87M | 403.31K | 561.88K | 558.77K | 637.77K | 987.83K | 600.31K | 709.57K | 1.07M | 2.21M | 1.41M | 1.08M | 134.42K | 149.39K | 168.60K | 157.18K |
| Cost & Expenses | 3.40M | 3.87M | 4.38M | 4.55M | 7.95M | 1.53M | 1.87M | 403.31K | 561.88K | 558.77K | 637.77K | 987.83K | 600.31K | 709.57K | 1.07M | 2.21M | 1.41M | 1.08M | 134.42K | 149.39K | 168.60K | 157.18K |
| Interest Income | 0.00 | 0.00 | 13.45K | 69.91K | 19.28K | 26.00 | 70.00 | 943.00 | 7.97K | 14.88K | 19.69K | 25.47K | 19.67K | 85.85K | 25.99K | 47.18K | 36.03K | 0.00 | 0.00 | 1.88K | 2.06K | 5.16K |
| Interest Expense | 7.83K | 6.93K | 7.92K | 7.22K | 9.22K | 7.43K | 1.31K | 951.00 | 943.00 | 975.00 | 1.01K | 921.00 | 10.03K | 1.38K | 1.45K | 2.06K | 1.94K | 0.00 | 0.00 | 856.00 | 691.00 | 557.00 |
| Depreciation & Amortization | 47.13K | 29.39K | 32.18K | 24.50K | 13.98K | 14.24K | 14.55K | 472.00 | 12.23K | 4.47K | 5.06K | 6.40K | 6.92K | 9.50K | 11.52K | 14.12K | 11.70K | 9.37K | 900.00 | 986.00 | 380.00 | 216.00 |
| EBITDA | -3.40M | -3.84M | -4.33M | -4.45M | -7.97M | -1.46M | -1.81M | -98.11K | -541.68K | -539.42K | -613.02K | -955.96K | -573.72K | -614.22K | 2.52M | -2.20M | -1.38M | -800.28K | -133.52K | -146.52K | -166.16K | -156.96K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -20,569.20% | 12,011.84% | -8,073.86% | 0.00% |
| Operating Income | -3.40M | -3.87M | -4.36M | -4.48M | -7.99M | -1.54M | -2.26M | -404.26K | -562.82K | -559.75K | -638.79K | -988.75K | -610.34K | -710.95K | -4.66M | -2.21M | -1.43M | -1.35M | -133.78K | -520.20K | -166.54K | -157.18K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -20,708.51% | -27,626.29% | -8,092.32% | 0.00% |
| Total Other Income/Expenses | 909.51K | -8.09M | -615.03K | 18.37K | 27.12K | -4.54K | -448.62K | 304.43K | -1.45M | 66.37K | -1.25M | -750.43K | 546.04K | -4.90M | -7.00M | 6.58K | 24.48K | -273.08K | 0.00 | 520.20K | 0.00 | 0.00 |
| Income Before Tax | -2.49M | -11.47M | -4.38M | -4.46M | -7.96M | -1.54M | -2.26M | -402.76K | -2.01M | -493.37K | -1.89M | -1.74M | -64.29K | -5.61M | -11.66M | -2.20M | -1.40M | -1.63M | 0.00 | -892.90K | 0.00 | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -47,419.17% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 6.93K | 7.92K | 7.22K | -43.04K | 7.43K | 1.31K | 951.00 | 943.00 | 975.00 | 1.01K | 921.00 | 10.03K | 1.38K | 3.56M | -45.12K | -16.30K | 272.84K | 456.00 | 373.56K | 691.00 | -5.16K |
| Net Income | -2.49M | -11.47M | -4.38M | -4.46M | -7.96M | -1.54M | -2.26M | -402.76K | -2.01M | -493.37K | -1.89M | -1.74M | -64.29K | -5.61M | -8.05M | -2.16M | -1.35M | -1.36M | -134.23K | -521.06K | -167.23K | -152.02K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -20,779.10% | -27,671.75% | -8,125.90% | 0.00% |
| EPS | -0.25 | -1.27 | -0.53 | -0.64 | -1.48 | -0.63 | -1.68 | -8.97 | -10.36 | -2.54 | -9.90 | -9.99 | -0.41 | -35.77 | -55.50 | -17.08 | -14.80 | -26.79 | -3.45 | -13.38 | -4.73 | -6.60 |
| EPS Diluted | -0.25 | -1.27 | -0.53 | -0.64 | -1.48 | -0.63 | -1.68 | -8.97 | -10.36 | -2.54 | -9.90 | -9.99 | -0.41 | -35.77 | -55.50 | -9.57 | -14.80 | -21.85 | -3.45 | -13.38 | -4.73 | -6.60 |
| Weighted Avg Shares Out | 10.00M | 9.05M | 8.30M | 6.95M | 5.37M | 2.45M | 1.34M | 44.88K | 194.46K | 194.05K | 191.18K | 174.11K | 157.77K | 156.95K | 145.09K | 126.35K | 91.14K | 50.60K | 38.96K | 38.96K | 35.34K | 23.04K |
| Weighted Avg Shares Out (Dil) | 10.00M | 9.05M | 8.30M | 6.95M | 5.37M | 2.45M | 1.34M | 44.88K | 194.46K | 194.05K | 191.18K | 174.11K | 157.77K | 156.95K | 145.09K | 225.35K | 91.14K | 62.04K | 38.96K | 38.96K | 35.34K | 23.04K |
Rapha Capital Leads New $3 Million Convertible Note Financing in Imagin Medical, Inc.
MIAMI and VANCOUVER, BC and BOSTON, Aug. 30, 2021 /PRNewswire/ -- Rapha Capital Management, LLC ("Rapha Capital") today announces it has closed a new convertible note offering totaling US $3 million in three tranches by Rapha Capital BioVentures Fund I, LP...
Imagin Medical Secures New $3 Million Convertible Note Financing
VANCOUVER, British Columbia, BOSTON and MIAMI, Aug. 26, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) today announces it has closed a new convertible note offering...
Imagin Medical on Schedule for American Urology Association Demonstration
VANCOUVER, British Columbia, and BOSTON, Aug. 17, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) today reports that the final design of the i/Blue Imaging...
IMAGIN MEDICAL REPORTS COMPANY ON SCHEDULE FOR PRODUCT DEMONSTRATION
Vancouver, B.C. and Boston, MA, May 19, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) today reported continued progress towards commercial-stage manufacturing capability with Lighthouse...
IMAGIN MEDICAL REPORTS MANUFACTURING PROGESS
VANCOUVER, B.C. / BOSTON, March 16, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) today reported continued progress towards commercial-stage manufacturing capability with Lighthouse Imaging...
IMAGIN MEDICAL CLOSES SECOND TRANCHE OF CONVERTIBLE NOTE OFFERING
Vancouver, B.C. and Boston, MA, Feb. 18, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD3) (“Imagin” or the “Company”) today announced that, further to its press releases of October...
Imagin Medical Engages Torrey Hills Capital
VANCOUVER, British Columbia, and BOSTON, Jan. 20, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) (FSE: DPD2) ("Imagin" or the "Company") is pleased to announce that it has engaged San Diego Torrey Hills Capital,...
Source: https://incomestatements.info
Category: Stock Reports